Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-23
2009-06-02
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S567000
Reexamination Certificate
active
07541355
ABSTRACT:
Methods for the racemization of an enantiomer of a 2,3-benzodiazepine molecule into the corresponding racemic mixture under either basic or acidic conditions are described. Furthermore, the invention relates to the conversion of an enantiomer of tofisopam or its metabolites to the corresponding opposite enantiomer.
REFERENCES:
patent: 3736315 (1973-05-01), Korosi et al.
patent: RE30014 (1979-05-01), Körosi et al.
patent: 4322346 (1982-03-01), Kórósi et al.
patent: 4423044 (1983-12-01), Kórösi et al.
patent: 5426215 (1995-06-01), Bertrand et al.
patent: 5621117 (1997-04-01), Bethge et al.
patent: 6080736 (2000-06-01), Landry et al.
patent: 6080887 (2000-06-01), Drauz et al.
patent: 6133446 (2000-10-01), TenBrink et al.
patent: 6458955 (2002-10-01), Gattuso
patent: 6638928 (2003-10-01), Harris et al.
patent: 6649607 (2003-11-01), Leventer et al.
patent: 6683072 (2004-01-01), Kucharik et al.
patent: 6864251 (2005-03-01), Kucharik et al.
patent: 7022700 (2006-04-01), Harris et al.
patent: 2004/0106602 (2004-06-01), Kucharik et al.
patent: 2004/0138209 (2004-07-01), Kucharik et al.
patent: 2004/0138210 (2004-07-01), Harris et al.
patent: 2004/0152695 (2004-08-01), Harris et al.
patent: 2004/0157833 (2004-08-01), Harris et al.
patent: 2004/0162284 (2004-08-01), Harris et al.
patent: 2004/0224943 (2004-11-01), Leventer et al.
patent: 2004/0229867 (2004-11-01), Kucharik
patent: 2004/0254174 (2004-12-01), Perrin et al.
patent: 2005/0075329 (2005-04-01), Leventer et al.
patent: 2005/0288277 (2005-12-01), Kucharik et al.
patent: 178516 (1983-03-01), None
patent: 178519 (1983-03-01), None
patent: WO 00/24400 (2000-05-01), None
I. Fitos, et al., “Separation of Enantiomers of Benzodiazepines on the Chiral-AGP Column”Journal of Chromatography A, 1995, 709, 265-73.
E. Fogassy, et al., “Studies on the Proerties and Structure of Optically Active 1-(3,4-Dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-Benzodiazepine (Tofisopam).” in H.C. Van der Plas, et al. (Eds.) “Bio-Organic Heterocycles Synthetic, Physical Organic and Pharmacological Aspects”, Elsevier, Amsterdam (1984).
E. J. Horvath, et al., “Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia”,Progress in Neurobiology, 2000, 60, 309-42.
M. Rizzo, “Chromatographic separation of 2,3-benzodiazepines”Journal of Chromatography B, 2000, 747, 203-16.
M. Simonyi, et al. “Stereoselective Binding of a 2,3-Bezodiazepine to Human Serum Albumin”,Biochemical Pharmacology, 1993, 32(12), 1917-20.
G. Toth, et al., Racemic Resolution of (+)-5-Ethyl-1(3,4-Dimethoxyphenyl)-6,7-Dimethoxy-4-Methyl-5H-2,3-Benzodiazepine and Anomalous Chiroptic Behavior of the Enantiomers (1),J. Heterocyclic Chem., 1983, 20, 709-13.
J. Visy, et al., “The Role of Configuration and Conformation in the Binding of 2,3-Benzodiazepines to Human Serum Albumin”Chirality, 1989, 1, 271-75.
Galbraith Kimm
Ravi Mallikarjun Reddy
Shi Jianfeng
Wang Wuyi
Wei Yong Victoria
Coleman Brenda L
Drinker Biddle & Reath LLP
Monaco Daniel A.
Vela Acquisition Corporation
LandOfFree
Conversion process for 2,3-benzodiazepine enantiomers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conversion process for 2,3-benzodiazepine enantiomers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conversion process for 2,3-benzodiazepine enantiomers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4144956